Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Divyanshu Dubey, Christopher A Cano & Olaf Stuve. (2015) Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab. Neuropsychiatric Disease and Treatment 11, pages 2405-2414.
Read now
Read now
Mark Willis & Neil P Robertson. (2014) Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opinion on Drug Safety 13:8, pages 1115-1124.
Read now
Read now
Fie Juhl Vojdeman, Jesper Jurlander, Mars van't Veer, Maija Itälä-Remes, Eva Kimby, Geir Erland Tjønnfjord, Jan Walewski, Tomas Kozák, Aaron Polliack, Michela Montagna, Mario Regazzi, Nikolai Kirkby, Marinus van Oers & Christian Hartmann Geisler. (2013) Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis. Leukemia & Lymphoma 54:4, pages 790-793.
Read now
Read now
Tamar Tadmor. (2011) Alemtuzumab (Campath-1H) for chronic lymphocytic leukemia: a drug in search of its optimal schedule. Leukemia & Lymphoma 52:10, pages 1831-1833.
Read now
Read now
Raimundo Fernando Bezares, German Stemelin, Alicia Diaz, Daniel Argentieri, Emilio Lanari Zubiaur, Guy Garay, Miguel Bartomioli, Ricardo Ryser & Gustavo Milone. (2011) Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leukemia & Lymphoma 52:10, pages 1936-1941.
Read now
Read now
Articles from other publishers (27)
Takuo Ogihara, Kenta Mizoi & Akiko Ishii-Watabe. (2023) Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design. Biomedicines 11:5, pages 1456.
Crossref
Crossref
Hussein M. Abdallah & Andy Z.X. Zhu. (2019) A Minimal Physiologically‐Based Pharmacokinetic Model Demonstrates Role of the Neonatal Fc Receptor (FcRn) Competition in Drug–Disease Interactions With Antibody Therapy. Clinical Pharmacology & Therapeutics 107:2, pages 423-434.
Crossref
Crossref
Rick Admiraal, Cornelia M. Jol-van der Zijde, Juliana M. Furtado Silva, Catherijne A. J. Knibbe, Arjan C. Lankester, Jaap Jan Boelens, Goeff Hale, Aniekan Etuk, Melanie Wilson, Stuart Adams, Paul Veys, Charlotte van Kesteren & Robbert G. M. Bredius. (2019) Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome. Clinical Pharmacokinetics 58:12, pages 1609-1620.
Crossref
Crossref
Marieke van der Zwan, Carla C. Baan, Teun van Gelder & Dennis A. Hesselink. (2017) Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. Clinical Pharmacokinetics 57:2, pages 191-207.
Crossref
Crossref
Michelle Willicombe, Dawn Goodall, Adam G McLean & David Taube. (2017) Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation - a retrospective study. Transplant International 30:11, pages 1110-1118.
Crossref
Crossref
Marzia CaldanoWilliam Raoul, Theo RispensAntonio Bertolotto. (2017) Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents. Therapeutic Drug Monitoring 39:4, pages 350-355.
Crossref
Crossref
Othman Al-Sawaf, Kirsten Fischer, Carmen D. Herling, Matthias Ritgen, Sebastian B?ttcher, Jasmin Bahlo, Thomas Elter, Stephan Stilgenbauer, Barbara F. Eichhorst, Raymonde Busch, Ute Elberskirch, Wolfgang Abenhardt, Michael Kneba, Michael Hallek & Clemens-Martin Wendtner. (2017) Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. European Journal of Haematology 98:3, pages 254-262.
Crossref
Crossref
TH Oude Munnink, MJ Henstra, LI Segerink, KLL Movig & P Brummelhuis-Visser. (2016) Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology. Clinical Pharmacology & Therapeutics 99:4, pages 419-431.
Crossref
Crossref
Rena Buckstein, Graeme Fraser, Matthew Cheung, Vishal Kukreti, John Kuruvilla, Kevin Imrie, Eugenia Piliotis, Gregory Pond, Jolanta Windsor, Zeina Ghorab, Kevin Shuoprasad, Ruth Turner, Ralph M. Meyer, Kathy Pritchard, Scott Walker, Mark Levine & Michael Crump. (2016) Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. Clinical Lymphoma Myeloma and Leukemia 16:1, pages 18-28.e4.
Crossref
Crossref
J S McCune, P Jacobson, A Wiseman & O Militano. (2014) Optimizing drug therapy in pediatric SCT: Focus on pharmacokinetics. Bone Marrow Transplantation 50:2, pages 165-172.
Crossref
Crossref
Benjamin R. Oshrine, Timothy S. Olson & Nancy Bunin. (2014) Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease. Pediatric Blood & Cancer 61:10, pages 1852-1859.
Crossref
Crossref
Carla Casulo, Julie M. Vose, William Y. Ho, Brad Kahl, Mark Brunvand, Andre Goy, Yvette Kasamon, Bruce Cheson & Jonathan W. Friedberg. (2014) A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. Clinical Immunology 154:1, pages 37-46.
Crossref
Crossref
Fuiyee Lee, Martha Luevano, Paul Veys, Kwee Yong, Alejandro Madrigal, Bronwen E. Shaw & Aurore Saudemont. (2014) The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface. PLoS ONE 9:7, pages e103254.
Crossref
Crossref
Charlotte I.S. Barker, Eva Germovsek, Rollo L. Hoare, Jodi M. Lestner, Joanna Lewis & Joseph F. Standing. (2014) Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. Advanced Drug Delivery Reviews 73, pages 127-139.
Crossref
Crossref
Shuang Bai, Rong Deng, Hong Xiang, Manish Gupta, Luna Musib, Banmeet Anand & Bert Lum. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
585
624
.
Claire Booth, Sarah Lawson & Paul Veys. (2013) The current role of T cell depletion in paediatric stem cell transplantation. British Journal of Haematology 162:2, pages 177-190.
Crossref
Crossref
C Booth & P Veys. (2013) T cell depletion in paediatric stem cell transplantation. Clinical and Experimental Immunology 172:2, pages 139-147.
Crossref
Crossref
Eva Perez-Pampin, Joaquin Campos-Franco, Jorge Blanco & Antonio Mera. (2013) Remission Induction in a Case of Refractory Behçet Disease With Alemtuzumab. Journal of Clinical Rheumatology 19:2, pages 101-103.
Crossref
Crossref
Teya M. Tietje, Douglas R. Allington & Michael P. Rivey. (2013) Alemtuzumab: A Place in Therapy for Treatment of Multiple Sclerosis. International Journal of Clinical Medicine 04:10, pages 459-471.
Crossref
Crossref
Andrew R. PettittRichard JacksonStacey CarruthersJames DoddSusanna DoddMelanie OatesGillian G. JohnsonAnna SchuhEstella MatutesClaire E. DeardenDaniel CatovskyJohn A. RadfordAdrian BloorGeorge A. FollowsStephen DevereuxAnton KrugerJulie BlundellSamir AgrawalDavid AllsupStephen ProctorEarnest HeartinDavid OscierTerry J. HamblinAndrew RawstronPeter Hillmen. (2012)
Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of
TP53
: Final Results of the National Cancer Research Institute CLL206 Trial
. Journal of Clinical Oncology 30:14, pages 1647-1655.
Crossref
Crossref
H.C. Kluin-Nelemans, M. van Marwijk Kooy, P.J. Lugtenburg, W.L.J. van Putten, M. Luten, J. Oudejans & G.W. van Imhoff. (2011) Intensified alemtuzumab–CHOP therapy for peripheral T-cell lymphoma. Annals of Oncology 22:7, pages 1595-1600.
Crossref
Crossref
Charlotte C. PetersenLine NederbyAnne S. RougAnni SkovboNiels A. PeterslundPeter HoklandBendt NielsenMarianne Hokland. (2011) Increased Expression of CD69 on T Cells as an Early Immune Marker for Human Cytomegalovirus Reactivation in Chronic Lymphocytic Leukemia Patients. Viral Immunology 24:2, pages 165-169.
Crossref
Crossref
T. Ng & A. Chan. (2011) Dosing modifications of targeted cancer therapies in patients with special needs: Evidence and controversies. Critical Reviews in Oncology/Hematology.
Crossref
Crossref
A.L. Young, N.R. LeBoeuf, S.J. Tsiouris, S. Husain & M.E. Grossman. (2010) Fatal disseminated Acanthamoeba infection in a liver transplant recipient immunocompromised by combination therapies for graft-versus-host disease. Transplant Infectious Disease 12:6, pages 529-537.
Crossref
Crossref
Jennifer Somerfield, Grant A. Hill-Cawthorne, Andrew Lin, Michael S. Zandi, Claire McCarthy, Joanne L. Jones, Michael Willcox, David Shaw, Sara A. J. Thompson, Alastair S. Compston, Geoff Hale, Herman Waldmann & Alasdair J. Coles. (2010) A Novel Strategy To Reduce the Immunogenicity of Biological Therapies. The Journal of Immunology 185:1, pages 763-768.
Crossref
Crossref
A Cortelezzi, M C Pasquini, A Gardellini, U Gianelli, A Bossi, G Reda, B Sarina, P Musto, W Barcellini, A Neri & G L Deliliers. (2009) Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23:11, pages 2027-2033.
Crossref
Crossref
Andreas Argyriou. (2009) . Molecular Medicine 15:7-8, pages 1.
Crossref
Crossref